CONFIDENTIAL Amendment # 4 to the Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated
EX-10.1 2 c55354_ex10-1.htm
Exhibit 10.1
CONFIDENTIAL
Amendment # 4 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated
| 1. | The purpose of this Amendment # 4 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) September 30, 2008, or (ii) the full execution of a new comprehensive Globale Clinical Trials Agreement. | |
| 2. | All other terms and conditions of the LOA shall remain in full force and effect. | |
| 3. | The parties hereto agree to this Amendment #4 to the LOA by their authorized signatures below. | |
| SMITHKLINE BEECHAM CORPORATION | QUEST DIAGNOSTICS INCORPORATED | |
| /s/ Paula M. Russella | /s/ Daniel P. Megronigle | |
| Paula M. Russella Sourcing Group Manager | Daniel P. Megronigle Executive Director, Sales & Marketing | |
| 25 July 2008 | 21 July 2008 | |
| Date | Date | |
Page 1 of 1
